(Total Views: 584)
Posted On: 08/22/2025 6:53:15 PM
Post# of 156685

The following comment that Jay made during the Aug 20 interview caught my eye. My apologies if this has already been discussed.
Perhaps it's just me, but a "bunch" of sites "actively enrolling" sounds like we have quite a few in the queue right now, which is very encouraging given that we only had a couple of patients enrolled a month or so ago.
Quote:
[00:30:10]: In the meantime we've started to enroll our Colorectal cancer study have a bunch of sites actively enrolling now and what we're going to be doing shortly is submitting a request to the FDA for a meeting at which point we're going to give them a rollover protocol for the Colorectal cancer patients that we're monitoring their PD-L1 status during the study and in the rollover protocol. We hope to then provide them a checkpoint inhibitor to see if we can replicate that clinical benefit, that survival benefit that we saw in the breast cancer patients.
Perhaps it's just me, but a "bunch" of sites "actively enrolling" sounds like we have quite a few in the queue right now, which is very encouraging given that we only had a couple of patients enrolled a month or so ago.


My comments are just my opinions and should NOT be taken as investment advice.